Grail, Inc. (NASDAQ:GRAL) Short Interest Update

Grail, Inc. (NASDAQ:GRAL) was the recipient of a large decline in short interest in the month of January. As of January 31st, there was short interest totalling 5,300,000 shares, a decline of 14.5% from the January 15th total of 6,200,000 shares. Currently, 18.9% of the shares of the company are short sold. Based on an average trading volume of 1,010,000 shares, the short-interest ratio is presently 5.2 days.

Grail Trading Up 4.6 %

Shares of GRAL stock opened at $55.02 on Friday. Grail has a 52 week low of $12.33 and a 52 week high of $55.32. The company’s fifty day simple moving average is $23.94 and its two-hundred day simple moving average is $18.11.

Insider Activity

In related news, CFO Aaron Freidin sold 30,452 shares of Grail stock in a transaction on Monday, November 18th. The shares were sold at an average price of $14.02, for a total transaction of $426,937.04. Following the transaction, the chief financial officer now owns 268,277 shares in the company, valued at approximately $3,761,243.54. The trade was a 10.19 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Institutional Trading of Grail

Several hedge funds have recently bought and sold shares of GRAL. Douglas Lane & Associates LLC purchased a new stake in Grail in the 4th quarter worth $3,034,000. A. D. Beadell Investment Counsel Inc. purchased a new stake in shares of Grail during the 4th quarter valued at about $430,000. FNY Investment Advisers LLC purchased a new stake in shares of Grail during the 4th quarter valued at about $26,000. 180 Wealth Advisors LLC purchased a new stake in shares of Grail during the 4th quarter valued at about $1,681,000. Finally, B & T Capital Management DBA Alpha Capital Management purchased a new stake in shares of Grail during the 4th quarter valued at about $387,000.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Grail in a research note on Wednesday, November 27th. They set an “equal weight” rating and a $16.00 target price on the stock. Wolfe Research assumed coverage on shares of Grail in a research note on Friday, November 15th. They set a “peer perform” rating on the stock.

Grail Company Profile

GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.